HCC: Key topics discussed at ASCO GI & EASL 2022

episode

COR2ED - Oncology Medical Conversation not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Essentials: How to Assess & Improve All Aspects of Your Fitness | Dr. Andy Galpin 35 min · 17 Sep 2026 · Huberman Lab

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

September 16, 2026 PC - Sep 16, 2026 1h 50m · 16 Sep 2026 · Fairfax County Planning Commission

Planning Commision 09/16/2026 - Sep 16, 2026 56 min · 16 Sep 2026 · Prince William County Planning Commission

Western Loudoun Rural Uses and Standards PCZOC Ad Hoc Meeting 2 - Sep 16, 2026 4h 45m · 16 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded06 Dec 2023

Publisherfeeds.castos.com ↗

Handlerec:7789310

Show notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in